People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...

Please provide your email address to receive an email when new articles are posted on . The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, ...

Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...

Hemophilia A patients manage the chronic disorder with infusions administered as frequently as every two to three days. The FDA has approved a Sanofi drug designed to last longer in the body, giving ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

While people with severe Hemophilia A can be treated with Factor VIII replacement products two to three times a week throughout their lifetime, this treatment is short-lived, expensive, and not always ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...

Interim findings showed, the estimated mean annualized bleeding rate for treated bleeds was 0.53, with a median ABR of 0. Topline results were announced from a phase 3 trial evaluating Mim8 in ...

ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...